A Phase 2, Open-label, Basket Study Investigating the Safety and Efficacy of GTX-102 in Adult and Pediatric Subjects with Deletion- or Nondeletion-type Angelman Syndrome
Angelman syndrome is a rare genetic condition affecting the nervous system. It often causes severe speech delays, movement issues, sleep problems, and learning challenges. Currently, treatments only help manage symptoms rather than targeting the root cause. This study is looking at an investigational medicine called GTX-102. Researchers want to find out whether it is safe and whether it can improve everyday quality of life. The study measures changes in thinking, understanding words, speaking, moving, and sleeping. Because this is an 'open-label' trial, there is no dummy drug (placebo); everyone taking part receives the study medicine. Participants will have regular clinic visits over approximately one year. During this time, clinical teams will carefully monitor safety and track progress to see if the treatment makes a meaningful difference.
At a glance
What is this study about?
Angelman syndrome is a lifelong genetic condition that affects how the brain develops. Children and adults with Angelman syndrome usually have severe speech difficulties, coordination problems, sleep disruptions, and distinct behavioural traits. At present, supportive therapies such as speech and physical therapy can help, but there are no approved medicines that address the underlying genetic cause.
This clinical trial is evaluating a new medicine called GTX-102. The drug is designed to target the specific genetic mechanism behind Angelman syndrome. The main goal of the trial is to see if GTX-102 is safe to give and to monitor any unwanted side effects closely. Doctors will also check whether the medicine helps improve key brain and body functions over the course of about a year.
Throughout the study, researchers will test different areas of development. These include thinking skills, how well a person understands others, how they communicate, how well they sleep, and how their motor skills or movements improve. By studying both deletion and non-deletion forms of the syndrome, researchers hope to see if this treatment can benefit a wide range of individuals.
Research like this is vital because discovering treatments that improve basic communication and motor skills could give people with Angelman syndrome greater independence and improve daily life for them and their families.
Key takeaways
- Tests an experimental drug called GTX-102 for people with Angelman syndrome.
- This is an open-label Phase 2 study, meaning all participants receive the active medicine.
- The study tracks safety, communication, motor skills, thinking, and sleep quality.
- Participation lasts roughly one year and requires regular clinic visits.
- Joining is entirely voluntary, and you can withdraw at any time without penalty.
Who may be eligible?
To take part in this study, participants must have a confirmed medical diagnosis of Angelman syndrome. This includes both the 'deletion' type (where a small piece of genetic material is missing) and 'non-deletion' types.
The study is designed to look at adults, and in some sub-groups, younger individuals as specified by the study team. Participants must be well enough overall to attend regular hospital appointments and take part in the tests.
People may not be able to join if they have other serious medical conditions that could make taking part unsafe, or if they are taking certain other medications that might interfere with the study drug. The clinical trial doctor will review each person's medical history to make sure taking part is appropriate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Has a confirmed medical diagnosis of Angelman syndrome (deletion or non-deletion type)
- Meets the age requirements set by the study site (such as adults aged 18 and older)
- Is able to travel to a participating specialist hospital for regular study visits
- Has a parent, guardian, or caregiver who can assist with assessments and appointments
- Does not have conflicting medical conditions that make trial participation unsafe
What does participation involve?
Taking part in this trial involves a commitment of around one year (about 338 days). During this time, participants will attend a specialist hospital clinic for treatment and regular check-ups.
At these visits, participants will receive the study medicine, GTX-102, along with supportive care. Doctors and nurses will check vital signs, take blood and other routine samples, and monitor closely for any side effects.
Caregivers and participants will also take part in developmental assessments. These checks involve simple tasks, puzzles, and questionnaires designed to measure thinking skills, spoken communication, movement, behaviour, and sleep patterns. Travel support or assistance may be available to help families attend these regular study visits.
Potential risks and benefits
Locations (3)
- —UnverifiedPortugal
- —UnverifiedItaly
- —UnverifiedFrance
Common questions
What does 'open-label' mean?
'Open-label' means that both you and the study doctors know you are receiving the real study medicine. There is no dummy drug or placebo used in this study.
Does this medicine cure Angelman syndrome?
No. GTX-102 is not a cure, but researchers hope it may treat some underlying features of the condition and improve symptoms like speech, movement, and sleep.
How long does the study last?
Participants are followed closely for about one year, with key health and progress checks taking place around day 338.
Will taking part cost anything?
The study medicine and all trial-related tests are provided free of charge. Studies often help cover travel and parking costs for clinic visits.
Can we stop taking part if we change our mind?
Yes. You or your family member can leave the study at any point, for any reason, and your regular NHS medical care will continue as normal.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.